People with bipolar disorder who take the weight-loss drug semaglutide face a 21 percent lower risk of psychiatric hospitalization, according to Griffith University researchers.
The finding comes from a 15-year study analyzing health data from nearly 15,000 bipolar patients in Sweden who were prescribed glucagon-like peptide-1 (GLP-1) receptor agonists. The research, published in the medical journal Acta Psychiatrica Scandinavica, compared periods when patients were actively taking semaglutide against periods when they were not receiving GLP-1 treatment.
Lead researcher Professor Mark Taylor said people with bipolar disorder who took semaglutide presented significantly lower rates of psychiatric hospitalization.
Taylor and his research team suggested GLP-1 signaling may protect the brain by reducing inflammation, cellular stress, and other biological processes involved in bipolar disorder. These protective mechanisms align with earlier scientific research on brain aging and neuroprotection, where GLP-1 compounds demonstrated an ability to modulate inflammatory pathways and enhance neuronal plasticity.
Bipolar disorder is a chronic mental health condition characterized by severe mood swings, including manic highs and depressive episodes. According to data from the World Health Organization (WHO), the condition affects approximately 37 million people worldwide. GLP-1 receptor agonists were originally developed to treat type 2 diabetes and obesity by regulating blood sugar levels and suppressing appetite. Semaglutide is commercially marketed under the brand names Ozempic and Wegovy.
Differences between diabetes medications
Although semaglutide showed a clear association with reduced psychiatric admissions, other GLP-1 receptor agonists evaluated in the study did not produce the same result. Patients prescribed liraglutide or dulaglutide did not experience a statistically significant reduction in psychiatric hospitalizations, indicating that psychiatric benefits may depend on specific molecular characteristics of individual drugs.
Griffith University is a public research institution based in Queensland, Australia. Researchers frequently utilize Sweden's national healthcare registries for long-term population studies because the Scandinavian nation maintains comprehensive, unified medical records across its healthcare system.
Impact on depression and the gut microbiome
Scientific interest in how GLP-1 medications affect mental health has expanded rapidly in recent years. Beyond bipolar disorder, investigators have been exploring the impact of GLP-1 therapies on depression, anxiety, and impulse control.
In animal models, liraglutide demonstrated an ability to reduce depressive behaviors through an unexpected biological mechanism involving the gut microbiome. Research published in the journal Cell Host & Microbe revealed that the medication increased populations of Lactobacillus delbrueckii, a gut bacterium that produces chemical compounds capable of regulating stress responses in the brain. When researchers removed that intestinal flora, the antidepressant effect of liraglutide completely disappeared, pointing to the gut-brain axis as a primary mediator.
The gut-brain axis is a complex two-way communication system linking the central nervous system with the gastrointestinal tract through neural, hormonal, and immunological signals. Microorganisms in the digestive tract produce neurotransmitters and metabolic byproducts that directly influence brain function and emotional regulation.
Anxiety, food cravings, and addiction research
While human data regarding GLP-1 drugs and mental health remains preliminary, several clinical trials have noted improvements in anxiety symptoms and food craving. Food craving represents a major behavioral component in eating disorders such as bulimia nervosa and binge eating disorder.
Scientists are also investigating whether GLP-1 receptor agonists can help reduce addictive behaviors, particularly alcohol consumption. However, researchers emphasize that findings regarding addiction treatment remain inconclusive at this stage.
Shared physiological pathways and comorbidity
The coexistence of obesity, type 2 diabetes, and bipolar disorder is common among psychiatric patients. Medical experts suspect these conditions share underlying pathophysiological pathways, including chronic systemic inflammation, insulin resistance, and mitochondrial dysfunction. If GLP-1 medications can target these shared mechanisms simultaneously, they could provide integrated therapeutic benefits for patients managing multiple complex conditions.
Despite the promising findings, the study authors urged caution in interpreting the results. The Swedish registry analysis was observational in design, meaning that while it established a robust statistical link, it cannot prove direct cause and effect. Taylor emphasized that randomized clinical trials will be necessary to confirm whether semaglutide can be formally established as a therapeutic tool for bipolar disorder.
GLP-1 drugs have already established clinical benefits extending well beyond metabolic health, including reducing cardiovascular risk, improving sleep apnea symptoms, and decreasing liver inflammation. Researchers are now working to determine whether medications originally created for diabetes management will become an unexpected component in treating complex psychiatric disorders.
